drugset / Trial / NCT07112196

Visugromab in Cachexia International Trial

NCT07112196

Phase 2/3 Recruiting 518 enrolled CatalYm GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.

Timeline

Start
2026-04-16
Primary completion
2029-12
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Visugromab Monoclonal antibody Intravenous

Indications

No indication recorded.